Detalhe da pesquisa
1.
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Breast Cancer Res Treat
; 198(3): 487-498, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36853577
2.
Quantitation of the ataxia-telangiectasia-mutated and Rad3-related inhibitor elimusertib (BAY-1895344) in human plasma using LC-MS/MS.
Biomed Chromatogr
; 36(11): e5455, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35876841
3.
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
Br J Clin Pharmacol
; 85(11): 2499-2511, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31271459
4.
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
Br J Clin Pharmacol
; 80(5): 1097-108, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26178713
5.
Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice.
Cancer Chemother Pharmacol
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38743253
6.
Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice.
Cancer Chemother Pharmacol
; 89(6): 795-807, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507041
7.
Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice.
Cancer Chemother Pharmacol
; 89(2): 231-242, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35066692
8.
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
Cancer Chemother Pharmacol
; 89(1): 49-58, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34669023
9.
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Cancer Chemother Pharmacol
; 89(5): 721-735, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35435472
10.
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
Clin Cancer Res
; 27(6): 1612-1622, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33203645
11.
In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine.
Cancer Chemother Pharmacol
; 86(5): 633-640, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32989483
12.
Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC-MS/MS.
J Pharm Biomed Anal
; 189: 113464, 2020 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32659569
13.
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
Cancer Chemother Pharmacol
; 85(4): 741-751, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32055930
14.
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
Leuk Lymphoma
; 61(2): 309-317, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31617432
15.
Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
Cancer Chemother Pharmacol
; 84(6): 1201-1208, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31522242
16.
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Cancer Chemother Pharmacol
; 83(2): 319-328, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30456480
17.
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
J Clin Oncol
; 37(29): 2601-2609, 2019 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31442103
18.
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
J Clin Invest
; 128(9): 3926-3940, 2018 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29952768
19.
LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma.
J Pharm Biomed Anal
; 134: 130-136, 2017 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27907855
20.
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.
J Pharm Biomed Anal
; 146: 154-160, 2017 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881312